Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BIIB054 · 1 trial · 2 indications
After a range of single BIIB054 doses administered as a single IV infusion in healthy participants and participants with early Parkinson's Disease, clinical laboratory test data, vital signs, neurological and physical examination findings, 12-lead electrocardiogram (ECG) data, and brain magnetic resonance imaging (MRI) findings will be used in the evaluation of AEs/SAEs.
The Columbia Suicide Severity Rating Scale, or C-SSRS, is a suicidal ideation rating scale created by researchers at Columbia University to evaluate suicidality.
The Montreal Cognitive Assessment MoCA is a brief cognitive screening tool for Mild Cognitive Impairment.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Single intravenous (IV) low dose infusion with staggered participant dosing |
| Cohort 2 | EXPERIMENTAL | Single IV ascending dose infusion with staggered participant dosing |
| Cohort 3 | EXPERIMENTAL | Single IV ascending dose infusion with staggered participant dosing |
| Cohort 4 | EXPERIMENTAL | Single IV ascending dose infusion with staggered participant dosing |
| Cohort 5 | EXPERIMENTAL | Single IV ascending dose infusion with staggered participant dosing |
| Cohort 6 | EXPERIMENTAL | Single IV ascending dose infusion with staggered participant dosing |
| Cohort 7 | EXPERIMENTAL | Single IV ascending dose infusion with staggered participant dosing |
| Name | Type | Description |
|---|---|---|
| BIIB054 | DRUG | IV infusion |
| Placebo | DRUG | IV infusion |
Key Inclusion Criteria: 1. All women of childbearing potential and all men must practice effective contraception during the study and for 6 months after their last dose of study treatment. 2. Must have a body mass index from 19 to 32 kg/m2, inclusive. 3. Must be in good health as determined by the ...
BIIB054 is an investigational small molecule being developed by Biogen Inc. for the treatment of Parkinson's disease. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and tolerability in early-stage trials.
BIIB054 is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. The drug is in Phase 1 clinical development for Parkinson's disease.
BIIB054 is in Phase 1 clinical development. It is an investigational drug for Parkinson's disease and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains in early-stage clinical testing.
BIIB054 has been studied in one completed Phase 1 clinical trial, identified as NCT02459886. This was a single-ascending dose study conducted in the United States that enrolled 66 participants, including healthy volunteers and individuals with early Parkinson's disease.
BIIB054 is the investigational name for this drug candidate developed by Biogen Inc. for Parkinson's disease. No alternative names have been established for this compound in the available clinical trial information.